Zhang Quan, Qiang Lei, Liu Yihao, Fan Minjie, Si Xinxin, Zheng Pengfei
Department of Orthopaedic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.
Jiangsu Key Laboratory of Marine Bioresources and Environment, Co-Innovation Center of Jiangsu Marine Bio-industry Technology, Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, Jiangsu Ocean University, Lianyungang, China.
Front Bioeng Biotechnol. 2023 Apr 7;11:1167474. doi: 10.3389/fbioe.2023.1167474. eCollection 2023.
Malignant bone tumors can inflict significant damage to affected bones, leaving patients to contend with issues like residual tumor cells, bone defects, and bacterial infections post-surgery. However, hydroxyapatite nanoparticles (nHAp), the principal inorganic constituent of natural bone, possess numerous advantages such as high biocompatibility, bone conduction ability, and a large surface area. Moreover, nHAp's nanoscale particle size enables it to impede the growth of various tumor cells diverse pathways. This article presents a comprehensive review of relevant literature spanning the past 2 decades concerning nHAp and bone tumors. The primary goal is to explore the mechanisms responsible for nHAp's ability to hinder tumor initiation and progression, as well as to investigate the potential of integrating other drugs and components for bone tumor diagnosis and treatment. Lastly, the article discusses future prospects for the development of hydroxyapatite materials as a promising modality for tumor therapy.
恶性骨肿瘤会对受影响的骨骼造成严重损害,使患者在术后面临残留肿瘤细胞、骨缺损和细菌感染等问题。然而,羟基磷灰石纳米颗粒(nHAp)作为天然骨骼的主要无机成分,具有高生物相容性、骨传导能力和大表面积等诸多优点。此外,nHAp的纳米级粒径使其能够通过多种途径抑制各种肿瘤细胞的生长。本文对过去20年中有关nHAp与骨肿瘤的相关文献进行了全面综述。主要目的是探索nHAp阻碍肿瘤发生和发展的机制,以及研究整合其他药物和成分用于骨肿瘤诊断和治疗的潜力。最后,本文讨论了羟基磷灰石材料作为一种有前景的肿瘤治疗方式的未来发展前景。